The TAPUR trial treated patients with pancreatic cancer harboring CDKN2A loss or mutation with the CDK4/6 inhibitor palbociclib, but failed to show any clinical response with palbociclib monotherapy34. This evidence concerns the gene CDK4 and pancreatic neoplasm.